{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:56:05Z","timestamp":1790074565963,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.2119\/molmed.2014.00214","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T15:13:38Z","timestamp":1437491618000},"page":"123-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia"],"prefix":"10.1186","volume":"21","author":[{"given":"Basile","family":"Stamatopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerence","family":"Crompot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Dessars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"El Housni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mineur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lagneaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,9]]},"reference":[{"key":"2101123_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.hoc.2013.01.002","volume":"27","author":"Y Herishanu","year":"2013","unstructured":"Herishanu Y, Katz BZ, Lipsky A, Wiestner A. (2013) Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol. Oncol. Clin. North Am. 27:173\u2013206.","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"2101123_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00277-002-0476-1","volume":"81","author":"T Hamblin","year":"2002","unstructured":"Hamblin T. (2002) Chronic lymphocytic leukaemia: one disease or two? Ann. Hematol. 81:299\u2013303.","journal-title":"Ann. Hematol."},{"key":"2101123_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.blre.2008.05.003","volume":"23","author":"F Bockstaele Van","year":"2009","unstructured":"Van Bockstaele F, Verhasselt B, Philippe J. (2009) Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 23:25\u201347.","journal-title":"Blood Rev."},{"key":"2101123_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/leu.2008.30","volume":"22","author":"M Fabbri","year":"2008","unstructured":"Fabbri M, et al. (2008) MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia. 22:1095\u2013105.","journal-title":"Leukemia"},{"key":"2101123_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281\u201397.","journal-title":"Cell"},{"key":"2101123_CR6","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1056\/NEJMp058190","volume":"353","author":"CZ Chen","year":"2005","unstructured":"Chen CZ. (2005) MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med. 353:1768\u201371.","journal-title":"N. Engl. J. Med."},{"key":"2101123_CR7","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1373\/clinchem.2010.147405","volume":"56","author":"JA Weber","year":"2010","unstructured":"Weber JA, et al. (2010) The microRNA spectrum in 12 body fluids. Clin. Chem. 56:1733\u201341.","journal-title":"Clin. Chem."},{"key":"2101123_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MOL.0b013e328350a425","volume":"23","author":"KC Vickers","year":"2012","unstructured":"Vickers KC, Remaley AT. (2012) Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 23:91\u20137.","journal-title":"Curr. Opin. Lipidol."},{"key":"2101123_CR9","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1073\/pnas.1019055108","volume":"108","author":"JD Arroyo","year":"2011","unstructured":"Arroyo JD, et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 108:5003\u20138.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2101123_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3816\/CLC.2009.n.001","volume":"10","author":"R Rosell","year":"2009","unstructured":"Rosell R, Wei J, Taron M. (2009) Circulating MicroRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer. Clin. Lung Cancer. 10:8\u20139.","journal-title":"Clin. Lung Cancer."},{"key":"2101123_CR11","doi-asserted-by":"publisher","first-page":"e3148","DOI":"10.1371\/journal.pone.0003148","volume":"3","author":"S Gilad","year":"2008","unstructured":"Gilad S, et al. (2008) Serum microRNAs are promising novel biomarkers. PLoS One. 3:e3148.","journal-title":"PLoS One"},{"key":"2101123_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1940-6207.CAPR-11-0370","volume":"5","author":"CC Pritchard","year":"2012","unstructured":"Pritchard CC, et al. (2012) Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila). 5:492\u20137.","journal-title":"Cancer Prev. Res. (Phila)."},{"key":"2101123_CR13","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105:10513\u20138.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2101123_CR14","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.1073\/pnas.1019557108","volume":"108","author":"E Moussay","year":"2011","unstructured":"Moussay E, et al. (2011) MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 108:6573\u20138.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"33","key":"2101123_CR15","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1038\/onc.2013.346","volume":"24","author":"Y He","year":"2014","unstructured":"He Y, Jiang X, Chen J. (2014) The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 24;33:3887\u201393.","journal-title":"Oncogene"},{"key":"2101123_CR16","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1182\/blood-2006-12-062398","volume":"109","author":"V Fulci","year":"2007","unstructured":"Fulci V, et al. (2007) Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 109:4944\u201351.","journal-title":"Blood"},{"key":"2101123_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood-2013-09-527234","volume":"124","author":"M Mraz","year":"2014","unstructured":"Mraz M, et al. (2014) MicroRNA-150 contributes to the proficiency of B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 genes. Blood. 124:84\u201395.","journal-title":"Blood"},{"key":"2101123_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/path.2333","volume":"215","author":"M Wang","year":"2008","unstructured":"Wang M, et al. (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC\/miR-155 expression. J. Pathol. 215:13\u201320.","journal-title":"J. Pathol."},{"key":"2101123_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2119\/molmed.2013.00005","volume":"19","author":"N Papakonstantinou","year":"2013","unstructured":"Papakonstantinou N, et al. (2013) Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol. Med. 19:115\u201323.","journal-title":"Mol. Med."},{"key":"2101123_CR20","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1373\/clinchem.2007.089326","volume":"53","author":"B Stamatopoulos","year":"2007","unstructured":"Stamatopoulos B, et al. (2007) Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin. Chem. 53:1757\u201366.","journal-title":"Clin. Chem."},{"key":"2101123_CR21","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1182\/blood-2008-11-189407","volume":"113","author":"B Stamatopoulos","year":"2009","unstructured":"Stamatopoulos B, et al. (2009) microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 113:5237\u201345.","journal-title":"Blood"},{"key":"2101123_CR22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1373\/clinchem.2010.157198","volume":"57","author":"JS McDonald","year":"2011","unstructured":"McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. (2011) Analysis of circulating microRNA: preanalytical and analytical challenges. Clin. Chem. 57:833\u201340.","journal-title":"Clin. Chem."},{"key":"2101123_CR23","doi-asserted-by":"publisher","first-page":"e12780","DOI":"10.1371\/journal.pone.0012780","volume":"5","author":"B Stamatopoulos","year":"2010","unstructured":"Stamatopoulos B, et al. (2010) A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. PLoS One. 5:e12780.","journal-title":"PLoS One"},{"key":"2101123_CR24","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood-2013-01-478222","volume":"122","author":"A Ferrajoli","year":"2013","unstructured":"Ferrajoli A, et al. (2013) Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia. Blood. 122:1891\u20139.","journal-title":"Blood"},{"key":"2101123_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3727\/096368911X582769b","volume":"22","author":"M Budoni","year":"2013","unstructured":"Budoni M, et al. (2013) The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transplant. 22:369\u201379.","journal-title":"Cell Transplant."},{"key":"2101123_CR26","doi-asserted-by":"publisher","first-page":"22492","DOI":"10.3402\/jev.v2i0.22492","volume":"2","author":"NM Mahaweni","year":"2013","unstructured":"Mahaweni NM, Kaijen-Lambers MEH, Dekkers J, Aerts JGJV, Hegmans JPJJ. (2013) Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma. J. Extracell. Vesicles. 2:22492.","journal-title":"J. Extracell. Vesicles."},{"key":"2101123_CR27","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","volume":"112","author":"LZ Rassenti","year":"2008","unstructured":"Rassenti LZ, et al. (2008) Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 112:1923\u201330.","journal-title":"Blood"},{"key":"2101123_CR28","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2013-09-527739","volume":"123","author":"M Ito","year":"2014","unstructured":"Ito M, et al. (2014) MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6 in advanced cutaneous T-cell lymphoma. Blood. 123:1499\u2013511.","journal-title":"Blood"},{"key":"2101123_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.yexmp.2014.02.015","volume":"96","author":"M Wang","year":"2014","unstructured":"Wang M, Yang W, Li M, Li Y. (2014) Low expression of miR-150 in pediatric intestinal Burkitt lymphoma. Exp. Mol. Pathol. 96:261\u20136.","journal-title":"Exp. Mol. Pathol."},{"key":"2101123_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/cas.12030","volume":"104","author":"T Yokobori","year":"2013","unstructured":"Yokobori T, et al. (2013) MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 104:48\u201354.","journal-title":"Cancer Sci."},{"key":"2101123_CR31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3892\/or.2012.2152","volume":"29","author":"Y Sun","year":"2013","unstructured":"Sun Y, et al. (2013) Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features. Oncol. Rep. 29:704\u201312.","journal-title":"Oncol. Rep."},{"key":"2101123_CR32","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/gutjnl-2011-301122","volume":"61","author":"Y Ma","year":"2012","unstructured":"Ma Y, et al. (2012) miR-150 as a potential bio-marker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 61:1447\u201353.","journal-title":"Gut."},{"key":"2101123_CR33","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/leu.2008.377","volume":"23","author":"M Mraz","year":"2009","unstructured":"Mraz M, et al. (2009) miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 23:1159\u201363.","journal-title":"Leukemia"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2014.00214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.2119\/molmed.2014.00214\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.crossref.org\/molmed.2014.00214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2014.00214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T01:26:24Z","timestamp":1554513984000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2014.00214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["2101123"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2014.00214","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"24 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}